Effectiveness of Thermal Ablation and Stereotactic Radiotherapy Based on Stage I Lung Cancer Histology

Hirsch, 2008, The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review, J Thorac Oncol, 3, 1468, 10.1097/JTO.0b013e318189f551 Cooper, 2006, Small cell lung cancer: treatment review, Respirology, 11, 241, 10.1111/j.1440-1843.2006.00850.x Howington, 2013, Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines, Chest, 143, e278S, 10.1378/chest.12-2359 Verstegen, 2015, Patterns of disease recurrence after SABR for early stage non–small-cell lung cancer: optimizing follow-up schedules for salvage therapy, J Thorac Oncol, 10, 1195, 10.1097/JTO.0000000000000576 Bahig, 2016, Severe radiation pneumonitis after lung stereotactic ablative radiation therapy in patients with interstitial lung disease, Pract Radiat Oncol, 6, 367, 10.1016/j.prro.2016.01.009 Chen, 2017, Treatment-related toxicity in patients with early-stage non-small cell lung cancer and coexisting interstitial lung disease: a systematic review, Int J Radiat Oncol Bio Phys, 98, 622, 10.1016/j.ijrobp.2017.03.010 Dupuy, 2011, Image-guided thermal ablation of lung malignancies, Radiology, 260, 633, 10.1148/radiol.11091126 Uhlig, 2018, Survival Rates after Thermal Ablation versus Stereotactic Radiation Therapy for Stage 1 Non–Small Cell Lung Cancer: A National Cancer Database Study, Radiology, 289, 862, 10.1148/radiol.2018180979 Bi, 2016, Comparison of the effectiveness of radiofrequency ablation with stereotactic body radiation therapy in inoperable stage I non-small cell lung cancer: a systematic review and pooled analysis, Int J Radiat Oncol Bio Phys, 95, 1378, 10.1016/j.ijrobp.2016.04.016 Hiraki, 2006, Pneumothorax, pleural effusion, and chest tube placement after radiofrequency ablation of lung tumors: incidence and risk factors, Radiology, 241, 275, 10.1148/radiol.2411051087 Thomas, 2015, Refining the treatment of NSCLC according to histological and molecular subtypes, Nat Rev Clin Oncol, 12, 511, 10.1038/nrclinonc.2015.90 Travis, 2015, The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification, J Thorac Oncol, 10, 1243, 10.1097/JTO.0000000000000630 Stuart, 2013, Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research, J Clin Epidemiol, 66, S84, 10.1016/j.jclinepi.2013.01.013 Freedman, 1982, Tables of the number of patients required in clinical trials using the logrank test, Stat Med, 1, 121, 10.1002/sim.4780010204 Videtic, 2017, Stereotactic body radiation therapy for early-stage non-small cell lung cancer: executive summary of an ASTRO evidence-based guideline, Pract Radiat Oncol, 7, 295, 10.1016/j.prro.2017.04.014 Ceniceros, 2016, Stereotactic body radiotherapy (SBRT) for the treatment of inoperable stage I non-small cell lung cancer patients, Clin Transl Oncol, 18, 259, 10.1007/s12094-015-1361-4 Bilal, 2012, Is radiofrequency ablation more effective than stereotactic ablative radiotherapy in patients with early stage medically inoperable non-small cell lung cancer?, Interact Cardiovasc Thorac Surg, 15, 258, 10.1093/icvts/ivs179 Kwan, 2014, Thermal ablation matches sublobar resection outcomes in older patients with early-stage non–small cell lung cancer, J Vasc Interv Radiol, 25, 1, 10.1016/j.jvir.2013.10.018 Rose, 2006, Lung cancer and radiofrequency ablation, J Vasc Interv Radiol, 17, 927, 10.1097/01.RVI.0000222707.44902.66 Lu, 2003, Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors, J Vasc Interv Radiol, 14, 1267, 10.1097/01.RVI.0000092666.72261.6B Ahmed, 2004, Radiofrequency ablation: effect of surrounding tissue composition on coagulation necrosis in a canine tumor model, Radiology, 230, 761, 10.1148/radiol.2303021801 Bertino, 2009, Pulmonary neuroendocrine/carcinoid tumors: a review article, Cancer, 115, 4434, 10.1002/cncr.24498 Chong, 2006, Neuroendocrine tumors of the lung: clinical, pathologic, and imaging findings, RadioGraphics, 26, 41, 10.1148/rg.261055057 Travis, 2013, New pathologic classification of lung cancer: relevance for clinical practice and clinical trials, J Clin Oncol, 31, 992, 10.1200/JCO.2012.46.9270 Wegner, 2019, Stereotactic body radiation therapy versus fractionated radiation therapy for early-stage bronchopulmonary carcinoid, Lung Cancer Manag, 8, LMT14, 10.2217/lmt-2019-0003 Colaco, 2015, Stereotactic radiotherapy in the treatment of primary bronchial carcinoid tumor, Clin Lung Cancer, 16, e11, 10.1016/j.cllc.2014.12.005 Rocco, 2016, Management of non-small cell lung cancer in the era of personalized medicine, Int J Biochem Cell Biol, 78, 173, 10.1016/j.biocel.2016.07.011 Jotte, 2015, Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance, Cancer Med, 4, 1621, 10.1002/cam4.506 Pakkala, 2018, Personalized therapy for lung cancer: striking a moving target, JCI Insight, 3, e120858, 10.1172/jci.insight.120858 Baine, 2018, Histology significantly affects recurrence and survival following SBRT for early stage non-small cell lung cancer, Lung Cancer, 118, 20, 10.1016/j.lungcan.2018.01.021 Ahmed, 2018, Radiosensitivity of lung metastases by primary histology and implications for stereotactic body radiation therapy using the genomically adjusted radiation dose, J Thorac Oncol, 13, 1121, 10.1016/j.jtho.2018.04.027 Jin, 2016, Personalized radiation therapy (PRT) for lung cancer, 175 Ager, 2019, Stereotactic body radiotherapy versus percutaneous local tumor ablation for early-stage non-small cell lung cancer, Lung Cancer, 138, 6, 10.1016/j.lungcan.2019.09.009 Wolf, 2019, Persistence of racial disparities in early-stage lung cancer treatment, J Thorac Cardiovasc Surg, 157, 1670, 10.1016/j.jtcvs.2018.11.108 Holmes, 2018, Racial disparities in time from diagnosis to treatment for stage I non–small cell lung cancer, JNCI Cancer Spectr, 2, 10.1093/jncics/pky007 Zhang, 2017, Propensity score analysis: more details, more credibility, J Clin Oncol, 35, 3265, 10.1200/JCO.2017.74.3641